JP2001510793A5 - - Google Patents

Download PDF

Info

Publication number
JP2001510793A5
JP2001510793A5 JP2000503829A JP2000503829A JP2001510793A5 JP 2001510793 A5 JP2001510793 A5 JP 2001510793A5 JP 2000503829 A JP2000503829 A JP 2000503829A JP 2000503829 A JP2000503829 A JP 2000503829A JP 2001510793 A5 JP2001510793 A5 JP 2001510793A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
methyl
carbon atoms
transplantation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000503829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001510793A (ja
JP4651191B2 (ja
Filing date
Publication date
Priority claimed from IT97MI001789A external-priority patent/IT1293795B1/it
Application filed filed Critical
Publication of JP2001510793A publication Critical patent/JP2001510793A/ja
Publication of JP2001510793A5 publication Critical patent/JP2001510793A5/ja
Application granted granted Critical
Publication of JP4651191B2 publication Critical patent/JP4651191B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000503829A 1997-07-28 1998-07-22 Mcp−1タンパク質の生成を減らす際に活性がある薬剤組成物 Expired - Fee Related JP4651191B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT97MI001789A IT1293795B1 (it) 1997-07-28 1997-07-28 Farmaco attivo nel ridurre la produzione di proteina mcp-1
IT97A01789 1997-07-28
PCT/EP1998/004924 WO1999004770A2 (en) 1997-07-28 1998-07-22 A pharmaceutical composition active in reducing production of mcp-1 protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009270715A Division JP5086322B2 (ja) 1997-07-28 2009-11-09 Mcp−1プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物

Publications (3)

Publication Number Publication Date
JP2001510793A JP2001510793A (ja) 2001-08-07
JP2001510793A5 true JP2001510793A5 (https=) 2006-01-05
JP4651191B2 JP4651191B2 (ja) 2011-03-16

Family

ID=11377642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000503829A Expired - Fee Related JP4651191B2 (ja) 1997-07-28 1998-07-22 Mcp−1タンパク質の生成を減らす際に活性がある薬剤組成物
JP2009270715A Expired - Fee Related JP5086322B2 (ja) 1997-07-28 2009-11-09 Mcp−1プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009270715A Expired - Fee Related JP5086322B2 (ja) 1997-07-28 2009-11-09 Mcp−1プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物

Country Status (15)

Country Link
US (1) US6534534B1 (https=)
EP (1) EP1005332B1 (https=)
JP (2) JP4651191B2 (https=)
AR (1) AR016382A1 (https=)
AT (1) ATE251902T1 (https=)
AU (1) AU744492B2 (https=)
CA (1) CA2300289C (https=)
DE (1) DE69819012T2 (https=)
DK (1) DK1005332T3 (https=)
ES (1) ES2207858T3 (https=)
IT (1) IT1293795B1 (https=)
PT (1) PT1005332E (https=)
SI (1) SI1005332T1 (https=)
WO (1) WO1999004770A2 (https=)
ZA (1) ZA986636B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
HRP20191953T8 (hr) * 2008-03-07 2021-06-25 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40
EP2262777B8 (en) * 2008-03-07 2016-05-04 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1
WO2009109613A2 (en) 2008-03-07 2009-09-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
EA019060B1 (ru) 2009-08-03 2013-12-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения с магнием
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011106611A2 (en) 2010-02-25 2011-09-01 Prairie Ventures, L.L.C. System and method for anatomical pathology sample handling, storage, and analysis
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
ES2789849T3 (es) * 2014-05-15 2020-10-26 Translatum Medicus Inc Composiciones y procedimientos para el tratamiento y diagnóstico de trastornos oculares
EP3942934A1 (en) 2015-06-12 2022-01-26 Vettore, LLC Mct4 inhibitors for treating disease
US10214492B2 (en) 2016-12-12 2019-02-26 Vettore, LLC Heterocyclic inhibitors of MCT4
WO2020261158A1 (en) 2019-06-25 2020-12-30 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
WO1994009128A1 (en) 1992-10-22 1994-04-28 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
JPH08333262A (ja) * 1995-04-07 1996-12-17 Chugai Pharmaceut Co Ltd 免疫抑制剤
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19538402A1 (de) * 1995-10-14 1997-04-17 Boehringer Mannheim Gmbh Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel
JPH09165339A (ja) * 1995-10-27 1997-06-24 American Home Prod Corp ラパマイシンを付与したドナー脾細胞を用いる臓器移植の延長
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1

Similar Documents

Publication Publication Date Title
JP2001510793A5 (https=)
Moskowitz et al. Experimentally induced degenerative joint lesions following partial meniscectomy in the rabbit
CY1109449T1 (el) Ενωσεις ουριας δραστικες ως ανταγωνιστες βανιλλοειδων υποδοχεων για την αντιμετωπιση του πονου
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
EP1159964A3 (en) Compositions and methods for stimulating gastrointestinal motility
WO2004103279A3 (en) 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
EP1797878A3 (en) Benzothiazole derivatives
JP2002525323A5 (https=)
EP0709376A3 (en) Therapeutic compounds
LU91761I2 (fr) Vernakalant et ses dérivés pharmaceutiquement acceptables et en particulier son sel d'hydrochlorure (BRINAVESS®)
JP2002518502A5 (https=)
EP2210892A3 (en) Neurologically-active compounds
GB9900334D0 (en) Tricylic vascular damaging agents
ATE433959T1 (de) Analoge von kokain
JP2002543202A5 (https=)
EP1891954A3 (en) Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
Zimmerman et al. Examination of an Aleutian mummy
EP0992509A3 (en) Novel macrolide derivatives
EP1431286A3 (en) Prodigiosin derivatives for treating cancer or viral diseases
EP1175900A3 (en) Use of growth hormone secretagogues for improvement of fucnctional health status
EP2364708A3 (en) Pharmaceutical composition comprising a ClC-2 channel opener
JP2001510793A (ja) Mcp−1タンパク質の生成を減らす際に活性がある薬剤組成物
SE0203526L (sv) New use of dextran sulfate
UA26204C2 (uk) Спосіб запобігаhhя деградації кісткового протеза
PT941110E (pt) Utilizacao do factor 2 de crescimento dos ceratinocitos